Table 4 QALYs in the therapy for breast cancer (2010, US $) 66.

Intervention	Incremental cost-efficiency ratio (ICER)
BRCA-1/2-test (age ≥ 35; family case history)	5 400 $/QALY
Raloxifen to reduce risk (age 55)	22 000 $/QALY
Letrozole vs. anastrozole (postmenopausal, HR+)	26 000 $/QALY
Lapatinib plus capecitabine vs. capecitabine	170 000 $/QALY
Yearly screening by MRI vs. mammography (BRCA1)	210 000 $/QALY
Bevacizumab plus paclitaxel vs. paclitaxel	280 000 $/QALY
Partial breast irradiation vs. whole breast irradiation (stage I, ER+, postmenopausal)	730 000 $/QALY
Digital mammography screening vs. film (age ≥ 40)	930 000 $/QALY